Pharmacokinetics of single daily dose gentamicin in children with cancer

Journal of Pediatric Hematology/Oncology

Volumn 21, Issue 4, 1999, Pages 284-288

  Shankar, Sadhna M ^a   Jew, Rita K ^b   Bickert, Betsy M ^b   Cavalieri, Gina E ^b   Bell, Louis M ^b   Lange, Beverly J ^b  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b NONE

Author keywords

Antibiotics; Cancer; Children; Gentamicin; Pharmacokinetics

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; GENTAMICIN;

ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL INFECTION; BACTERICIDAL ACTIVITY; CENTRAL VENOUS CATHETER; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG METABOLISM; FEVER; HUMAN; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL; PSEUDOMONAS;

ANTIBIOTICS, ANTINEOPLASTIC; CATHETERIZATION, CENTRAL VENOUS; CHILD; CHILD, PRESCHOOL; DRUG ADMINISTRATION SCHEDULE; FEMALE; GENTAMICINS; HUMANS; INFUSIONS, INTRAVENOUS; MALE; PROSPECTIVE STUDIES;

EID: 0033512651     PISSN: 10774114     EISSN: None     Source Type: Journal    
DOI: 10.1097/00043426-199907000-00008     Document Type: Article

References (31)

1. Lacy MK, Nicolau DP, Nightingale CH, Quintiliani R. The pharmacodynamics of aminoglycosides. Clin Infect Dis 1998;27:23-7.
2. Kapusnik JE, Hackbarth CJ, Chambers HF, et al. Single, large, daily dosing versus intermittent dosing of tobramycin for treating experimental pseudomonas pneumonia. J Infect Dis 1988;158:7-12.
3. Vogelman B, Craig WA. Kinetics of antimicrobial activity. J Pediatr 1986;108:835-40.
4. Verpooten GA, Giuliano RA, Verbist L. et al. Once daily dosing decreases renal accumulation of gentamicin and netilmicin and their nephrotoxicities. Clin Pharmacol Ther 1989;45:22-7.
5. Moore RD, Smith CR, Leitman PS. The association of aminoglycoside plasma levels with mortality in patients with gram-negative bacteremia. J Infect Dis 1984;49:443-8.
6. Moore RD, Smith CR, Leitman PS. Association of plasma levels with therapeutic outcome in gram negative pneumonia. Am J Med 1984;77:657-62.
7. Vogelman BS, Craig WA. Post antibiotic effects. J Antimicrob Chemother 1985;15:37-46.
8. Nicolau DP, Freeman D, Belliveau PP, et al. Experience with once daily aminoglycoside program administered to 2184 adult patients. Antimicrob Agents Chemother 1995;39:650-5.
9. Chan GL. Alternative dosing strategy for aminoglycosides: impact on efficacy, nephrotoxicity, and ototoxicity. Drug Intelligence Clin Pharm 1989;23:188-94.
10. Bates RD, Nahata MC. Once daily administration of aminoglycosides. Ann Pharmacother 1994;28:757-65.
11. Blaser J, Konig C. Once daily dosing of aminoglycosides. Eur J Clin Microb Infect Dis 1995;14:1029-38.
12. Sawchuk RJ, Zaske DE, Cippolle RJ, et al. Kinetic model for gentamicin dosing with the use of individual patient parameters. Clin Pharmacol Ther 1976;21:362-9.
13. Vogelman B, Gundmundsson S, Turnidge J, et al. In vivo postantibiotic effect in neutropenic mice. J Infect Dis 1988;157:287-98.
14. Moore RD, Smith CR, Leitman PS. Risk factors for development of auditory toxicity in patients receiving aminoglycosides. J Infect Dis 1984;149:23-30.
15. Lerner AM, Cone LA, Jansen W, et al. Randomized controlled trial of the efficacy, auditory toxicity, and nephrotoxicity of tobramycin and netilmicin. Lancet 1983;1:1123-5.
16. Moore RD, Leitman PS, Craig RS. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimum inhibitory concentration. J Infect Dis 1987;155:93-9.
17. Van Horn KG, Gedris C, Ahmed A. Bacteremia and urinary tract infection associated with CDC group Vd biorar 2. J Clin Microbiol 1989;27:201-2.
18. Postovsky S, Ben Arush MW, Kassis E, et al. Pharmacokinetic analysis of gentamicin thrice and single daily dosage in pediatric cancer patients. Pediatr Hematol Oncol 1997;14:547-54.
19. Shankar A, Sharma SD. Gentamicin as once daily dose therapy in recurrent urinary tract infections in children. Curr Ther Res 1987; 41:599-603.
20. Elhanan K, Siplovich L, Raz R. Gentamicin once daily versus thrice daily in children. J Antimicrob Chemother 1995;35:327-32.
21. Kafetzis DA, Sianidou L, Vlachos E, et al. Clinical and pharmacokinetic study of a single daily dose of amikacin in pediatric patients with severe gram-negative infections. J Antimicrob Chemother 1991;27(Suppl C):105-12.
22. Viscoli C, Dudley M, Ferrea G, Boni L, et al. Serum concentrations and safety of a single daily dosing of amikacin in children undergoing bone marrow transplantation. J Antimicrob Chemother 1991;27(Suppl C):113-20.
23. Vigano A, Principi N, Brivio L, et al. Comparison of 5 milligrams of netilmicin per kilogram of body weight once daily versus 2 milligrams per kilogram thrice daily for treatment of gram-negative pyelonephritis in children. Antimicrob Agents Chemother 1992;36:1499-503.
24. Prins JM, Buller HR, Kuijper EJ, et al. Once versus thrice daily gentamicin in patients with serious infections. Lancet 1993;341: 335-9.
25. Raz R, Adawin M, Romano S. Intravenous administration of gentamicin once daily versus thrice daily in adults. Eur J Clin Microbiol Infect Dis 1995;14:88-91.
26. Powell SH, Thompson WL. Luthe MA, et al. Once daily vs. continuous aminoglycoside dosing: efficacy and toxicity in animal and clinical studies of gentamicin, netilmicin, and tobramycin. J Infect Dis 1983;147:918-32.
27. Mallor R, Isaksson B, Nilsson L. A study of amikacin given once versus twice daily in serious infections. J Antimicrob Chemother 1988;22:75-9.
28. Tulkens PM. Efficacy and safety of aminoglycosides once a day: experimental and clinical data. Scand J Infect Dis 1991;74:249-57.
29. Ter Braak EW, deVries PJ, Bouter KP, et al. Once daily dosing for aminoglycosides plus beta-lactum combination therapy of serious bacterial infections: comparative trial with netilmicin and ceftriaxone. Am J Med 1990;89:58-66.
30. Hessen MT, Pitsakis PG, Levison ME. Absence of postantibiotic effect in experimental pseudomonas endocarditis treated with imipenem with or without gentamicin. J Infect Dis 1988;158:542-8.
31. Gavalda J, Cardona PJ, Almirante B. et al. Antimicrob Agents Chemother 1996;40:173-8.